Artificial Intelligence ‘outsmarts cancer’

_89918322_c0264776-breast_cancer_cell,_sem-splEarly trial data shows a drug developed using artificial intelligence can slow the growth of cancer in clinical trials.

The data, presented at the American Society of Clinical Oncology conference, showed some tumours shrank by around a quarter. The compound will now be taken into more advanced trials.

Scientists said we were now in an explosive stage of merging advances in computing with medicine. Spotting every difference between a cancerous and a healthy cell is beyond even the brightest human minds. So the US biotechnology company Berg has been feeding as much data as its scientists could measure on the biochemistry of cells into a supercomputer. The aim was to let an artificial intelligence suggest a way of switching a cancerous cell back to a healthy one.

READ MORE

About Peter Coffaro 1060 Articles
A growth-driven and strategic executive, Peter Coffaro commands more than 20 years of progressive management success within the medical device industry. As a District Sales Manager for Stryker Orthopaedics, Peter was responsible for managing and directing a regional sales force to achieve sales and profit goals within the Rocky Mountain region. Previously, he was the Director of Sales & Marketing for Amp Orthopedics. In this role, Peter was responsible for planning, developing, and leading all sales and marketing initiatives. Peter is a former orthopedic distributor in the Pacific Northwest. He has also worked with DePuy Orthopaedics as well as Zimmer, and held positions in sales, sales training, and sales management. Peter has an extensive background in organizational development, business development, sales management, negotiating and P&L management. Peter holds a B.S. degree in Biology from Northern Illinois University.

Be the first to comment

Leave a Reply

Your email address will not be published.


*